NCCN Publishes New Patient Education Resources for Patients with Chronic Lymphocytic Leukemia and Hodgkin Lymphoma—a Rare, Yet Curable, Cancer
New patient education resources from NCCN empower patients with Chronic Lymphocytic Leukemia and Hodgkin Lymphoma to work alongside their physicians to make informed decisions about their treatment.
FORT WASHINGTON, PA — To further educate people with Chronic Lymphocytic Leukemia (CLL) and Hodgkin Lymphoma about the most effective treatment options for their disease, the National Comprehensive Cancer Network® (NCCN®) has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ series for CLL and Hodgkin Lymphoma, the newest additions to NCCN’s library of patient education resources. NCCN has also published NCCN Quick Guides™ to complement the latest edition of the NCCN Guidelines for Patients®: Chronic Myelogenous Leukemia (CML).
CLL is the most prevalent adult leukemia in Western countries[i], and it is estimated that, in 2016, more than 18,000 people will be diagnosed with CLL in the United States[ii].
The NCCN Guidelines for Patients®: CLL is the first in a series of resources dedicated to patient education for Non-Hodgkin’s Lymphomas; subsequent resources outlining treatment options for Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mycosis Fungoides, and Peripheral T-Cell Lymphoma will be published this year.
Because of clinical advances over the past three decades, Hodgkin Lymphoma, although rare, is curable in at least 80 percent of patients with five-year survival rates that are unmatched in any other cancer.[iii]
The NCCN Guidelines for Patients and NCCN Quick Guide™ series for Hodgkin Lymphoma have been broken out into three distinct sections to provide users with information most pertinent to their diagnosis: Treatment Overview, Classical Hodgkin Lymphoma, and Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Made available through support of the NCCN Foundation®, the NCCN Guidelines for Patients and NCCN Quick Guide™ series for CLL, CML, and Hodgkin Lymphoma are available to download free of charge on NCCN.org/patients; for information about print copies, visit NCCN.org/patients.
“Through providing free resources for people with these blood cancers, NCCN Foundation strives to empower patients by providing insight into their treatment options, allowing them to work alongside their care team to make informed decision about their care,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation.
The NCCN Guidelines for Patients, translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), are designed to provide people with cancer and their caregivers with state-of-the-art treatment information in easy-to-understand language. The NCCN Guidelines® are developed by multidisciplinary panels of experts from NCCN Member Institutions and feature algorithms that address appropriate management options from initial work-up through the course of the disease.
NCCN Guidelines for Patients and NCCN Quick Guide™ series, abbreviated references outlining key points of the NCCN Guidelines for Patients, are written according to plain language principles to improve health literacy, and the design and format feature patient-friendly elements, such as medical illustrations of anatomy, tests, and treatments. These resources also feature an expansive glossary of terms and acronyms. The NCCN Guidelines for Patients and the NCCN Quick Guide™ series do not replace the expertise and clinical judgment of the physician.
NCCN currently offers NCCN Guidelines for Patients for the following: Breast, Colon, Esophageal, Kidney, Non-Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Acute Lymphoblastic Leukemia; Caring for Adolescents and Young Adults (AYA); Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkin Lymphoma; Lung Cancer Screening, Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; and Soft Tissue Sarcoma.
To download or order the NCCN Guidelines for Patients and NCCN Quick Guide™ series for CLL or Hodgkin Lymphoma, visit NCCN.org/patients.
###
About NCCN Foundation
Through philanthropy, the NCCN Foundation® empowers people through knowledge and advances the mission of NCCN to improve the quality, effectiveness, and efficiency of cancer care, so that patients can live better lives.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the nation’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients.
[i] "NCCN Guidelines for Non-Hodgkin Lymphomas, V 2.2016." NCCN.org. National Comprehensive Cancer Network, 17 Feb. 2016. Web. 22 Feb. 2016
[ii] "Cancer Facts & Figures 2016." American Cancer Society. Web. 22 Feb. 2016.
[iii] "NCCN Guidelines for Hodgkin Lymphoma, V 2.2015." NCCN.org. National Comprehensive Cancer Network, 20 Apr. 2015. Web. 8 Dec. 2015.
Katie Kiley Brown, NCCN
215.690.0238
Tags:
